PREFER: Open science, open access

The PREFER project is committed to open science. We have promised our funders, the Innovative Medicines Initiative, to ensure all our publications are available to those who do not have, or cannot afford, subscritpions to scientific journals. This is made possible through postprint publishing in the Uppsala University library's DiVA database, also known as green open access.

Open access publication is an important part of open science. The PREFER project has decided to use the "green" route for most of our publications, making postprints available in a public database, after the journal's embarbo ends. This is also known as "parallel publishing" and means that the authors' version (before the journal layout) becomes available after a fixed period of time (that varies between journals).

To date, two publications have been made available using the green route:

de Bekker-Grob, Esther W.; Juhaeri, Juhaeri; Kihlbom, Ulrik; Levitan, Bennett et al., Giving patients' preferences a voice in the medical product lifecycle: why, when and how?: The public-private PREFER project: Work package 2, ISPOR Value & Outcomes Spotlight, p. 19 19-21 21, 2018.

Download fulltext

de Bekker-Grob, Esther; Berlin, Conny; Levitan, Bennet; Raza, Karim et al., Giving Patients’ Preferences a Voice in Medical Treatment Life Cycle: The PREFER Public–Private Project, Patient, p. 263-266, 2017.

Download fulltext

This is the first step to honouring our commitment to open access publication. In the future, PREFER will ensure that all of our publications are made available, either through the journal (aka "gold" open access) or through the DiVA repository.

By Josepine Fernow

More PREFER publications


 

CONTACT US

X: @IMI_PREFER

LinkedIn

YouTube

  •  
  • Disclaimer: This website and its contents reflects the PREFER project's view and not the view of IMI, the European Union or EFPIA.
  •  

PREFER

The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).